Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

Adicet Bio (ACET)

Adicet Bio Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ACET
DateTimeSourceHeadlineSymbolCompany
24/06/202412:00Business WireAdicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell CarcinomaNASDAQ:ACETAdicet Bio Inc
07/06/202421:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACETAdicet Bio Inc
07/06/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACETAdicet Bio Inc
07/06/202421:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACETAdicet Bio Inc
07/06/202421:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACETAdicet Bio Inc
07/06/202421:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACETAdicet Bio Inc
07/06/202421:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACETAdicet Bio Inc
05/06/202412:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACETAdicet Bio Inc
05/06/202412:00Business WireAdicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus NephritisNASDAQ:ACETAdicet Bio Inc
31/05/202422:41Business WireAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACETAdicet Bio Inc
29/05/202412:00Business WireAdicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare ConferenceNASDAQ:ACETAdicet Bio Inc
14/05/202421:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACETAdicet Bio Inc
14/05/202421:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACETAdicet Bio Inc
14/05/202421:01Business WireAdicet Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:ACETAdicet Bio Inc
14/05/202415:00Business WireAdicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid CongressNASDAQ:ACETAdicet Bio Inc
10/05/202411:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACETAdicet Bio Inc
07/05/202412:00Business WireAdicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences ConferenceNASDAQ:ACETAdicet Bio Inc
30/04/202422:10Business WireAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACETAdicet Bio Inc
22/04/202421:30Business WireAdicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingNASDAQ:ACETAdicet Bio Inc
08/04/202412:00Business WireAdicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual ConferenceNASDAQ:ACETAdicet Bio Inc
28/03/202421:19Business WireAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACETAdicet Bio Inc
19/03/202420:10Business WireAdicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:ACETAdicet Bio Inc
11/03/202411:00Business WireAdicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceNASDAQ:ACETAdicet Bio Inc
01/03/202400:46Business WireAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACETAdicet Bio Inc
05/02/202421:01Business WireAdicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:ACETAdicet Bio Inc
02/02/202416:49Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ACETAdicet Bio Inc
31/01/202421:39Business WireAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACETAdicet Bio Inc
27/01/202400:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACETAdicet Bio Inc
27/01/202400:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACETAdicet Bio Inc
25/01/202421:01Business WireAdicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional SharesNASDAQ:ACETAdicet Bio Inc
 Showing the most relevant articles for your search:NASDAQ:ACET